

# APASL STC 2025 Tokyo Sponsored Seminars Program

**Day 1: October 2 (Thursday) 2025**

Room 1 “Cosmos Hall” 3<sup>rd</sup> Floor

**12:00-13:00 Luncheon Seminar 1 (Gilead Sciences K.K.)**

---

*Moderator: Dr. Shuji Terai (Japan)*

**LS1-1 Real-World Evidence of Sofosbuvir/Velpatasvir and Post-SVR Strategies for HCC Risk Reduction**

Dr. Jia-Horng Kao (Taiwan)

**LS1-2 From HCV to SLD: Cutting-edge Research in Liver Disease**

Dr. Hayato Nakagawa (Japan)

**15:40-16:40 Teatime Seminar 1 (Novo Nordisk Pharma Ltd.)**

---

*Moderator: Dr. Kenichi Ikejima (Japan)*

**TS1-1 Proposals for the Management of MASLD/MASH in Japan**

Dr. Yoichi Hiasa (Japan)

**TS1-2 Management of MASLD/MASH: Current Situation and Challenges**

Dr. Hideki Fujii

# APASL STC 2025 Tokyo Sponsored Seminars Program

**Day 1: October 2 (Thursday) 2025**

Room 2 “Orion” 5<sup>th</sup> Floor

**12:00-13:00 Luncheon Seminar 2 (Boehringer Ingelheim)**

---

*Moderator: Dr. Atsushi Nakajima (Japan)*

**LS2-1 MASLD Pathogenesis: Focus on Cellular Stress Responses**

Dr. Kanji Yamaguchi (Japan)

**LS2-2 MASLD as a Condition Necessitating Decisions on the Management and Risk Reduction of Lifestyle-Related Diseases**

Dr. Hirokazu Takahashi (Japan)

**15:40-16:40 Teatime Seminar 2 (AbbVie G.K.)**

---

*Moderator: Dr. Naoya Sakamoto (Japan)*

**TS2-1 Efficacy of HCV Treatment and Challenges in Disease Progression Following Viral Eradication**

Dr. Nobuharu Tamaki (Japan)

**TS2-2 Prediction of Hepatocellular Carcinoma by Serum Biomarkers**

Dr. Taro Yamashita (Japan)

**17:40-18:30 Evening Seminar (Miyarisan Pharmaceutical Co., Ltd.)**

---

*Moderator: Dr. Tetsuo Takehara (Japan)*

**ES-1 Harnessing the Liver–Brain–Gut Axis: A Novel Vagal Stimulation Strategy for Intestinal Treg Regulation**

Dr. Takanori Kanai (Japan)

**ES-2 Targeting Goblet Cell Pathways to Prevent Microbial Translocation and Alcohol-Associated Liver Disease**

Dr. Bernd Schnabl (USA)

# APASL STC 2025 Tokyo Sponsored Seminars Program

**Day 2: October 3 (Friday) 2025**

Room 1 “Cosmos Hall” 3<sup>rd</sup> Floor

**08:00-09:00 Morning Seminar 1 (Gilead Sciences K.K.)**

---

*Moderator: Dr. Yasuhito Tanaka (Japan)*

**MS1-1 A New Era in the Management for Hepatitis B: Toward Treatment Optimization Based on Basic Research and Clinical Data**

Dr. Takahiro Kodama (Japan)

**MS1-2 Cardiometabolic Disease and Chronic Hepatitis B**

Dr. Vincent W.S. Wong (Hong Kong SAR, China)

**12:00-13:00 Luncheon Seminar 3 (AbbVie G.K.)**

---

*Moderator: Dr. Masayuki Kurosaki (Japan)*

**LS3-1 Current Landscape of HCV: Epidemiology, Treatment, and Long-Term Outcomes after HCV Cure**

Dr. Eiichi Ogawa (Japan)

**LS3-2 A New Era of Liver Care: MASLD and Post-SVR Outcomes**

Dr. Takumi Kawaguchi (Japan)

# APASL STC 2025 Tokyo Sponsored Seminars Program

**Day 2: October 3 (Friday) 2025**

Room 2 “Orion” 5<sup>th</sup> Floor

**08:00-09:00 Morning Seminar 2 (Nobelpharma Co., Ltd)**

---

*Moderator: Dr. Hitoshi Yoshiji (Japan)*

**MS2-1 Zinc Supplementation in the Treatment of Liver Cirrhosis**

Dr. Nobuhiro Nakamoto (Japan)

**MS2-2 The Role of Zinc in the Management of Hepatocellular Carcinoma**

Dr. Ryosuke Tateishi (Japan)

**12:00-13:00 Luncheon Seminar 4 (Meiji Seika Pharma Co., Ltd.)**

---

*Moderator: Dr. Satoshi Mochida (Japan)*

**LS4-1 Validating the JSH Cirrhosis Guidelines from Real-world Clinical Data in Japan**

Dr. Masanori Atsukawa (Japan)

**LS4-2 Nutritional Therapy for Cirrhosis – Effects of BCAA on Prevention of Liver Failure –**

Dr. Masahito Shimizu (Japan)